Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions

pharmacodynamics

  • WCK 5222 (Cefepime-Zidebactam) Pharmacodynamic Target Analysis against Metallo-β-Lactamase-Producing <em>Enterobacteriaceae</em> in the Neutropenic Mouse Pneumonia Model
    Experimental Therapeutics
    WCK 5222 (Cefepime-Zidebactam) Pharmacodynamic Target Analysis against Metallo-β-Lactamase-Producing Enterobacteriaceae in the Neutropenic Mouse Pneumonia Model

    WCK 5222 is a combination of cefepime and the novel β-lactam enhancer (BLE) zidebactam. Zidebactam has a dual mechanism of action involving high-affinity penicillin binding protein 2 (PBP2) binding as well as inhibition of Ambler class A and C enzymes.

    Alexander J. Lepak, Miao Zhao, David R. Andes
  • Modeling and Simulation of Pretomanid Pharmacodynamics in Pulmonary Tuberculosis Patients
    Pharmacology
    Modeling and Simulation of Pretomanid Pharmacodynamics in Pulmonary Tuberculosis Patients

    Pretomanid (PA-824) is a nitroimidazole in clinical testing for the treatment of tuberculosis. A population pharmacodynamic model for pretomanid was developed using a Bayesian analysis of efficacy data from two early bactericidal activity (EBA) studies, PA-824-CL-007 and PA-824-CL-010, conducted in Cape Town, South Africa.

    Michael A. Lyons
  • Observational, Prospective Single-Center Study of Antibiotic Prophylaxis with High-Dose Cefoxitin in Bariatric Surgery
    Pharmacology
    Observational, Prospective Single-Center Study of Antibiotic Prophylaxis with High-Dose Cefoxitin in Bariatric Surgery

    The optimal dose of cefoxitin for antibiotic prophylaxis in obese patients remains uncertain. We evaluated the adequacy of a 4-g dosing regimen of cefoxitin against the most common pathogens that infect patients undergoing bariatric surgery. This observational prospective study included obese patients who required bariatric surgery and a 4-g dose of cefoxitin as an antibiotic prophylaxis. Serum concentrations were measured during...

    Thibaut Belveyre, Philippe Guerci, Elise Pape, Nathalie Thilly, Kossar Hosseini, Laurent Brunaud, Nicolas Gambier, Claude Meistelman, Marie-Reine Losser, Julien Birckener, Julien Scala-Bertola, Emmanuel Novy
  • Determination of Pharmacodynamic Target Exposures for Rezafungin against <span class="named-content genus-species" id="named-content-1">Candida tropicalis</span> and <span class="named-content genus-species" id="named-content-2">Candida dubliniensis</span> in the Neutropenic Mouse Disseminated Candidiasis Model
    Experimental Therapeutics
    Determination of Pharmacodynamic Target Exposures for Rezafungin against Candida tropicalis and Candida dubliniensis in the Neutropenic Mouse Disseminated Candidiasis Model

    Rezafungin (CD101) is a novel echinocandin under development for once-weekly intravenous (i.v.) dosing. We evaluated the pharmacodynamics (PD) of rezafungin against 4 Candida tropicalis and 4 Candida dubliniensis strains, using the neutropenic mouse invasive candidiasis model. The area under the...

    Alexander J. Lepak, Miao Zhao, David R. Andes
  • Amikacin Initial Dose in Critically Ill Patients: a Nonparametric Approach To Optimize <em>A Priori</em> Pharmacokinetic/Pharmacodynamic Target Attainments in Individual Patients
    Pharmacology
    Amikacin Initial Dose in Critically Ill Patients: a Nonparametric Approach To Optimize A Priori Pharmacokinetic/Pharmacodynamic Target Attainments in Individual Patients

    Amikacin is commonly used for probabilistic antimicrobial therapy in critically ill patients with sepsis. Its narrow therapeutic margin makes it challenging to determine the right individual dose that ensures the highest efficacy target attainment rate (TAR) in this setting. This study aims to develop a new initial dosing approach for amikacin by optimizing the a priori TAR in this population.

    Clément Boidin, Laurent Bourguignon, Sabine Cohen, Claire Roger, Jean-Yves Lefrant, Jason A. Roberts, Bernard Allaouchiche, Alain Lepape, Arnaud Friggeri, Sylvain Goutelle
  • Open Access
    Epithelial Lining Fluid and Plasma Concentrations of Dalbavancin in Healthy Adults after a Single 1,500-Milligram Infusion
    Clinical Therapeutics
    Epithelial Lining Fluid and Plasma Concentrations of Dalbavancin in Healthy Adults after a Single 1,500-Milligram Infusion

    Dalbavancin is a lipoglycopeptide antibiotic with a prolonged half-life. A phase 1 study assessed dalbavancin levels in epithelial lining fluid (ELF) in 35 healthy adults using ELF bronchial microsampling up to 168 h after administration of 1,500 mg dalbavancin. The penetration of dalbavancin into ELF was 36%. ELF levels of dalbavancin exceeded the MIC90s of ...

    Urania Rappo, Michael W. Dunne, Sailaja Puttagunta, James S. Baldassarre, Shengfang Su, Daksha Desai-Krieger, Megumi Inoue
  • Kinetic Driver of Antibacterial Drugs against <em>Plasmodium falciparum</em> and Implications for Clinical Dosing
    Pharmacology
    Kinetic Driver of Antibacterial Drugs against Plasmodium falciparum and Implications for Clinical Dosing

    Antibacterial drugs are an important component of malaria therapy. We studied the interactions of clindamycin, tetracycline, chloramphenicol, and ciprofloxacin against Plasmodium falciparum under static and dynamic conditions. In microtiter plate assays (static conditions), and as expected, parasites displayed the delayed death response characteristic for apicoplast-...

    Emily Caton, Elizabeth Nenortas, Rahul P. Bakshi, Theresa A. Shapiro
  • <em>In Vivo</em> Pharmacodynamic Target Determination for Delafloxacin against <span class="named-content genus-species" id="named-content-1">Klebsiella pneumoniae</span> and <span class="named-content genus-species" id="named-content-2">Pseudomonas aeruginosa</span> in the Neutropenic Murine Pneumonia Model
    Experimental Therapeutics
    In Vivo Pharmacodynamic Target Determination for Delafloxacin against Klebsiella pneumoniae and Pseudomonas aeruginosa in the Neutropenic Murine Pneumonia Model

    Delafloxacin is a broad-spectrum anionic fluoroquinolone that has completed a phase 3 study for community-acquired bacterial pneumonia. We investigated the pharmacodynamic target for delafloxacin against 12 Klebsiella pneumoniae and 5 Pseudomonas aeruginosa strains in the neutropenic murine lung...

    Miao Zhao, Alexander J. Lepak, Karen Marchillo, David R. Andes
  • Impact of Triazole Therapeutic Drug Monitoring Availability and Timing
    Clinical Therapeutics
    Impact of Triazole Therapeutic Drug Monitoring Availability and Timing

    Therapeutic drug monitoring (TDM) is an established strategy to optimize antifungal therapy with certain triazoles. While established relationships exist between concentration and safety or efficacy, the impact of TDM timing on outcomes is unknown. We report clinical outcomes, including antifungal exposure and mortality, in patients receiving institutional versus reference laboratory TDM.

    Erin K. McCreary, Meg Bayless, Ahn P. Van, Alexander J. Lepak, Donald A. Wiebe, Lucas T. Schulz, David R. Andes
  • Model-Based Relationship between the Molecular Bacterial Load Assay and Time to Positivity in Liquid Culture
    Editor's Pick Pharmacology
    Model-Based Relationship between the Molecular Bacterial Load Assay and Time to Positivity in Liquid Culture

    The molecular bacterial load (MBL) assay is a new tuberculosis biomarker which provides results in ∼4 hours. The relationship between MBL and time-to-positivity (TTP) has not been thoroughly studied, and predictive models do not exist. We aimed to develop a model for MBL and identify the MBL-TTP relationship in patients.

    Robin J. Svensson, Wilber Sabiiti, Gibson S. Kibiki, Nyanda E. Ntinginya, Nilesh Bhatt, Geraint Davies, Stephen H. Gillespie, Ulrika S. H. Simonsson

Pages

  • Next
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 12
Back to top

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

Copyright © 2019 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596